Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

Por Sanchez Spitman, A. B., Moes, D. J. A. R., Gelderblom, H., Dezentje, V. O., Swen, J.J., Guchelaar, H. J.
Publicado no Eur J Clin Pharmacol (2017)

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy

Por Sanchez-Spitman, A. B., Dezentjé, V. O., Swen, J. J., Moes, D. J. A. R., Gelderblom, H., Guchelaar, Henk-Jan
Publicado no Breast Cancer Res Treat (2018)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

Por Dezentjé, V. O., Opdam, F. L., Gelderblom, H., Hartigh den, J., Van der Straaten, T., Vree, R., Maartense, E., Smorenburg, C. H., Putter, H., Dieudonné, A. S., Neven, P., Van de Velde, C. J. H., Nortier, J. W. R., Guchelaar, H.-J.
Publicado no Breast Cancer Res Treat (2015)